INTRODUÇÃO: O melanoma cutâneo constitui cerca de 3% de todos os tumores da pele. Atinge indivíduos jovens com média de idade de aparecimento entre 50 e 58 anos. Em torno de 20% dos doentes apresentarão doença avançada e morrerão antes de completar cinco anos de sobrevida. CASUÍSTICA E MÉTODOS: Neste estudo retrospectivo de 364 casos acompanhados de maio de 1993 a janeiro de 2006 descreveram-se as variáveis: sexo, idade, cor, localização da lesão primária, tipo de crescimento, espessura de Breslow, nível de Clark, presença de ulceração, estadiamento e suas correlações. RESULTADOS: Predominou o sexo feminino (58,8%) resultando em uma proporção de 1,4 mulheres para cada homem. A média das idades dos pacientes foi de 58,9 anos e a mediana de 61,0 anos. Pacientes não-brancos constituíram 13,7% da amostra. Para homens e mulheres o melanoma cutâneo localizou-se, predominantemente no tronco (24,3-38,0%) e pés (21,4-23,9%). O melanoma acrolentiginoso representou 22,3% de toda amostra. Os padrões melanoma expansivo superficial e melanoma nodular (p < 0,001) e lesões no tronco (52,8%) predominaram nos indivíduos brancos. O melanoma acrolentiginoso (64%) e a localização nos pés (68,2%)prevaleceram nos pacientes não-brancos. Observou-se minoria de casos com lesão primária in situ (14,6%- EC 0) e alto percentual de melanoma cutâneo espesso (39,7% > 4,0 mm). Presença de ulceração foi observada em 13,4% para tumores finos (= 1,0 mm). Homens apresentaram lesões mais espessas (p = 0,011) e ulceradas (p < 0,001) em relação às mulheres, assim como idosos em relação à não idosos (p = 0,021 para a espessura e p = 0,015 para ulceração). A sobrevida média para os pacientes com doença localizada foi de 97,8 meses e a taxa de sobrevida específica para melanoma cutâneo foi de 85,1% em três anos. CONCLUSÕES: Esta amostra constituiu-se de pacientes com tumores espessos e ulcerados denotando diagnóstico tardio do melanoma cutâneo e pior prognóstico. Caracterizou-se por apresentar predomínio de mulheres, de pacientes não-brancos, de lesões nas extremidades e de melanoma acrolentiginoso. / INTRODUCTION: Cutaneous melanoma represents around 3% of all skin tumors. Affecting young patients, with mean age between 50 and 58 years old. About 20% of the patients will have advanced disease and will die before five years of survival. CASUISTIC AND METHODS: In this retrospective study of 364 cases recorded from May 1993 to January 2006 at the Melanoma Unit of Santa Casa de São Paulo the following variables were described: sex, age, skin color, tumor site, growth pattern, tumor thickness, Clark level, ulceration, staging and their correlations. RESULTS: Female (58,8%) prevailed resulting in 1,4 women for each man. The mean age of the patients was 58,9 years old and the median, 61,0 years old. Non-white patients were 13,7% of the sample. The anatomic site of cutaneous melanoma on men and women prevailed at trunk (24,3 – 38,0%) and feet (21,4 – 23,9%). Acral entiginous melanoma represented 22,3% of the cohort. Superficial expansive melanoma and nodular melanoma patterns (p<0,001) and trunk lesions (52,8%) predominated on white patients. Acral lentiginous melanoma (64%) and feet anatomic site 68,2%) prevailed on non-white patients. In situ primary lesions were observed in few cases (14,6% - EC 0) and there was high percentage of thick cutaneous melanoma (39,7% > 4,0 mm). In thin tumors (=1,0 mm) were found 13,4% of ulceration. Thickener (p = 0,011) and ulcerated lesions (p < 0,001) were found more in male and in elderly patients (p = 0,021 for thickeness and p = 0,015 for ulceration). The mean survival of patients with local disease was 97,8 months and the three-year survival rate for cutaneous melanoma was 85,1%. CONCLUSIONS: The cohort consisted mostly of thick and ulcerated tumors, which meant late diagnosis and bad prognosis. Also distinguished by considerable prevalence of female, non-white patients, limb lesions and acral lentiginous melanoma.

The aim of this research was to explore consumer perceptions of personalised nutrition and to compare these across three different levels of "medicalization": lifestyle assessment (no blood sampling); phenotypic assessment (blood sampling); genomic assessment (blood and buccal sampling). The protocol was developed from two pilot focus groups conducted in the UK. Two focus groups (one comprising only "older" individuals between 30 and 60 years old, the other of adults 18-65 yrs of age) were run in the UK, Spain, the Netherlands, Poland, Portugal, Ireland, Greece and Germany (N=16). The analysis (guided using grounded theory) suggested that personalised nutrition was perceived in terms of benefit to health and fitness and that convenience was an important driver of uptake. Negative attitudes were associated with internet delivery but not with personalised nutrition per se. Barriers to uptake were linked to broader technological issues associated with data protection, trust in regulator and service providers. Services that required a fee were expected to be of better quality and more secure. An efficacious, transparent and trustworthy regulatory framework for personalised nutrition is required to alleviate consumer concern. In addition, developing trust in service providers is important if such services to be successful.

Indiana University-Purdue University Indianapolis (IUPUI) / Russian demographic statistics reflect the persistence of a dramatically wide gender gap in life expectancy and mortality over the last decades - about twice that found in the developed world. On average, men in Russia live 12 years less than Russian women, and 14.5 years less than men in Western Europe. This thesis provides an overview and synthesis of the most recently available literature that addresses the persistent gender gap in mortality and life expectancy in Russia. I reviewed the prevalent behavioral and social-structural drivers that explain the causes of higher male mortality in contemporary Russia. Especially, I looked at how the conceptualization of the male social role and related norms that shape masculine behavior contribute to high male mortality in Russia. The study reveals that men’s unhealthy, risky behavior and their higher vulnerability to stress are considered to be linked to their gendered social identity which is created and reproduced by the social-structural context of the Russia’s society.

PURPOSE: To determine the influence of race/ethnicity on outcomes in the Childhood Cancer Survivor Study (CCSS). PATIENTS AND METHODS: Of CCSS adult survivors in the United States, 443 (4.9%) were black, 503 (5.6%) were Hispanic and 7,821 (86.6%) were white. Mean age at interview, 26.9 years (range, 18 to 48 years); mean follow-up, 17.2 years (range, 8.7 to 28.4 years). Late mortality, second malignancy (SMN) rates, health care utilization, and health status and behaviors were assessed for blacks and Hispanics and compared with white survivors. RESULTS: Late mortality rate (6.5%) and 15-year cumulative incidence of SMN (3.5%) were similar across racial/ethnic groups. Minority survivors were more likely to have lower socioeconomic status (SES); final models were adjusted for income, education, and health insurance. Although overall health status was similar, black survivors were less likely to report adverse mental health (females: odds ratio [OR], 0.6; 95% CI, 0.4 to 0.9; males: OR, 0.5; 95% CI, 0.3 to 0.8). Differences in health care utilization and behaviors noted: Hispanic survivors were more likely to report a cancer center visit (females: OR, 1.5; 95% CI, 1.1 to 2.0; males: OR, 1.7; 95% CI, 1.2 to 2.3); black females were more likely (OR, 1.6; 95% CI, 1.1 to 2.4), and Hispanic females less likely to have a recent Pap smear (OR, 0.7; 95% CI, 0.5 to 1.0); black and Hispanic survivors were less likely to report smoking; black survivors were less likely to report problem drinking. CONCLUSION: Adjusted for SES, adverse outcomes in CCSS were not associated with minority status. Importantly, black survivors reported less risky behaviors and better preventive practices. Hispanic survivors had equitable access to cancer related care.